A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin

Clinical Pharmacokinetics

Volumn 49, Issue 10, 2010, Pages 661-669

  Bockbrader, Howard N ^a   Wesche, David ^a   Miller, Raymond ^a   Chapel, Sunny ^a   Janiczek, Nancy ^a   Burger, Paula ^a  

^a PFIZER INC   (United States)

Author keywords

antiepileptic drugs; epilepsy; gabapentin; pharmacodynamics; pharmacokinetics; pregabalin; seizures

Indexed keywords

GABAPENTIN; MORPHINE; PLACEBO; PREGABALIN;

AREA UNDER THE CURVE; BLURRED VISION; CLINICAL TRIAL; CONFUSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EPILEPSY; GASTROINTESTINAL ABSORPTION; HUMAN; KIDNEY CLEARANCE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

AMINES; ANALGESICS; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GAMMA-AMINOBUTYRIC ACID;

EID: 77956360935     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11536200-000000000-00000     Document Type: Review

References (51)

1. Gee NS, Brown JP, Dissanayake VUK, et al. The novel anticonvulsant drug, gabapentin (Neurontin®), binds to the a2d subunit of a calcium channel. J Biol Chem 1996 Mar; 271 (10): 5768-5776
2. Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel a2d ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007 Feb; 28 (2): 75-82
3. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel a2-d (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007 Feb; 73 (2): 137-150
4. Field MJ, Cox PJ, Stott E, et al. Identification of the a2-d-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci\USA 6 Nov; 103 (46): 17537-17542
5. Belliotti TR, Capiris T, Ekhato IV, et al. Structure-activity relationships of pregabalin and analogues that target the a2-d protein. J Med Chem 2005 Apr; 48 (7): 2294-2307
6. Timmerman W, Bouma M, De Vries JB, et al. A microdialysis study on the mechanism of action of gabapentin. Eur J Pharmacol 2000 Jun; 398 (1): 53-57
7. Stringer JL, Aribi AM. Modulation of the in vivo effects of gabapentin by vigabatrin and SKF89976A. Epilepsy Res 2002 Dec; 52 (2): 129-137
8. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006 Feb; 6 (1): 108-113
9. Thurlow RJ, Brown JP, Gee NS, et al. [3H]Gabapentin may label a system-L-like neutral amino acid carrier in brain. Eur J Pharmacol 1993 Nov; 247 (3): 341-345
10. Wesche D, Bockbrader HN. A pharmacokinetic comparison of pregabalin and gabapentin [abstract]. J Pain 2005; 6 Suppl. 3: S29
11. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport me-chanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993 Feb; 10 (2): 276-281
12. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related com-pounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002 Apr; 61 (4): 729-737
13. Berry DJ, Beran RG, Plunkeft MJ, et al. The absorption of gabapentin fol-lowing high dose escalation. Seizure 2003 Jan; 12 (1): 28-36
14. Bockbrader HN. Clinical pharmacokinetics of gabapentin. Drugs of Today 1995; 318: 613-619
15. Piyapolrungroj N, Li C, Bockbrader H, et al. Mucosal uptake of gabapentin (neurontin) vs pregagablin in the small intestine. Pharm Res 2001 Aug; 18 (8): 1126-1130
16. Su TZ, Feng MR, Weber ML. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther 5 Jun; 313 (3): 1406-1415
17. Busch J, Strand J, Posvar E, et al. Pregabalin (CI-1008) multiple-dose pharmacokinetics and safety/tolerence in healthy volunteers [abstract]. Pharm Sci 9; 1: 2033
18. Radulovic LL, Turck D, von Hodenberg A, et al. Disposition of gabapentin (Neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos 1995 Apr; 23 (4): 441-448
19. Bockbrader HN, Radulovic LL, Strand JC, et al. Regional differences in the colonic absorption of pregabalin [abstract no. CI-1008]. Pharm Sci 0; 2: 2080
20. Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010 Aug; 50 (8): 941-950
21. Bockbrader HN, Breslin EM, Uderwood BA, et al. Multiple-dose, dose-proportionality study of Neurontin® (gabapentin) in healthy volunteers [abstract]. Epilepsia 1996; 37 (S5): 159
22. Corrigan BW, Pool WF, Posvar EL, et al. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin Pharmacol Ther 1; 69 (2): P18 [online]. Available from URL: http://www. nature. com/clpt/journal/ v69/n2/pdf/clpt200111a. pdf [Accessed 2010 Jun 30]
23. Gidal BE, Radulovic LL, Kruger S, et al. Inter-and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000 Jul; 40 (2-3):-7
24. Alvey C, Bockbrader H, Gonyea-Polski S, et al. An oral, rising, single-and multiple-dose, tolerance and pharmacokinetic study of pregabalin (CI-1008) capsules in healthy volunteers. New York: Pfizer Inc., 0 Mar 13. (Data on file)
25. Busch J, Gonyea-Polski S, Posvar EL, et al. An oral, rising single-dose toler-ance and pharmacokinetic study of CI-1008 solution and capsule doses in health volunteers. New York: Pfizer Inc., 2 Jan 8. (Data on file)
26. Gidal BE, Maly MM, Budde J, et al. Effect of a high-protein meal on gaba-pentin pharmacokinetics. Epilepsy Res 1996 Feb; 23 (1): 71-76
27. Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986 May; 36 (5): 830-839
28. Ben-Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and gaba-pentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. Epilepsy Res 1992 Mar; 11 (1): 45-49
29. Buvanendran A, Kroin JS, Reuban SS, et al. Cerebrospinal fluid bioavailability of oral pregabalin [abstract no. S-206]. Anesth Analg 8; 106 (3S): S-206 [online]. Available from URL:/3S-Suppl/S1. full. pdf+html [Accessed 2010 Jun 30]
30. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Phar-macokinet 2007; 46 (3): 209-219
31. Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during deliv-ery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia 2005 Oct; 46 (10): 1621-1624
32. Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003 Mar; 43 (3): 277-283
33. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994 Aug; 56 (2): 154-159
34. Wilson EA, Sills GJ, Forrest G,et al. High dose gabapentin inrefractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res 1998 Jan; 29 (2): 161-166
35. Eckhardt K, Ammon S, Hofmann U, et al. Gabapentin enhances the analgesic effectofmorphine inhealthy volunteers. Anesth Analg 2000 Jul; 91(1): 185-91 Data on file, Pfizer Inc., 5
36. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006 Mar; 61 (3): 246-255
37. Aills M, Allen R, Bockbrader HN, et al. A 5-week, double-blind, placebo-controlled, parallel-group study of pregabalin (75 and 150 mg/day) in patients with postherpetic neuralgia. New York: Pfizer Inc., 2001 Oct 15. (Dataonfile)
38. Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003 Apr; 60 (8): 1274-1283
39. Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001 Nov; 94 (2): 215-224
40. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998 Dec; 280 (21): 1837-1842
41. Sabatowski R, Galvez R, Cherry DA, et al., 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 4 May; 109 (1-2): 35
42. van Seventer R, Feister HA, Young JP, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006 Feb; 22 (2): 375-384
43. Kowalski K, Burger P, Miller R, et al. Exposure response relationship of pregabalin: a novel therapy for the treatment of neuropathic pain [abstract]. Eur J Neurol 2003; 10 Suppl. 1: 36-37
44. Chapel S, Kowalski K, Hutmacher M, et al. Pregabalin exposure-response analysis in patients with postherpetic neuralgia [abstract no. PII-143]. Clin Pharmacol Ther 5; 77 (2): P88 [online]. Available from URL: http://www. nature. com/clpt/journal/v77/n2/pdf/clpt2005340a. pdf [Accessed 2010 Jun 30]
45. Gabapentin in partial epilepsy. UK Gabapentin Study Group. Lancet 1990 May 335. 8698. 1114-1117
46. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5. Neurology 1993 Nov; 43 (11): 2292-2298
47. Anhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994 Jul-Aug; 35 (4): 795-801
48. Beydoun A, Uthman BM, Kugler AR, et al., Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 5 Feb; 64 (3): 475-480
49. Arroyo S, Anhut H, Kugler AR, et al., Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 4 Jan; 45 (1): 20-27
50. French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003 May; 60 (10): 1631-1637
51. Eisenberg E, River Y, Shifrin A, et al. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007; 67 (9): 1265-1289